Next Article in Journal
Detection of Ancient Viruses and Long-Term Viral Evolution
Previous Article in Journal
Exploring the Mumps Virus Glycoproteins: A Review
Previous Article in Special Issue
Evolution of Anti-RBD IgG Avidity following SARS-CoV-2 Infection
Article

Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies

Department of Microbiology, NYU Grossman School of Medicine, New York, NY 10016, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Lianpan Dai
Viruses 2022, 14(6), 1334; https://doi.org/10.3390/v14061334
Received: 20 May 2022 / Revised: 15 June 2022 / Accepted: 16 June 2022 / Published: 18 June 2022
(This article belongs to the Special Issue Basic Sciences for the Conquest of COVID-19)
The recent emergence of the Omicron BA.1 and BA.2 variants with heavily mutated spike proteins has posed a challenge to the effectiveness of current vaccines and to monoclonal antibody therapy for severe COVID-19. After two immunizations of individuals with no history of previous SARS-CoV-2 infection with BNT162b2 vaccine, neutralizing titer against BA.1 and BA.2 were 20-fold decreased compared to titers against the parental D614G virus. A third immunization boosted overall neutralizing titers by about 5-fold but titers against BA.1 and BA.2 remained about 10-fold below that of D614G. Both Omicron variants were highly resistant to several of the emergency use authorized therapeutic monoclonal antibodies. The variants were highly resistant to Regeneron REGN10933 and REGN10987 and Lilly LY-CoV555 and LY-CoV016 while Vir-7831 and the mixture of AstraZeneca monoclonal antibodies AZD8895 and AZD1061 were significantly decreased in neutralizing titer. Strikingly, a single monoclonal antibody LY-CoV1404 potently neutralized both Omicron variants. View Full-Text
Keywords: SARS-CoV-2 variants; COVID-19; Omicron BA.2; monoclonal antibodies; spike protein SARS-CoV-2 variants; COVID-19; Omicron BA.2; monoclonal antibodies; spike protein
Show Figures

Figure 1

MDPI and ACS Style

Zhou, H.; Dcosta, B.M.; Landau, N.R.; Tada, T. Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies. Viruses 2022, 14, 1334. https://doi.org/10.3390/v14061334

AMA Style

Zhou H, Dcosta BM, Landau NR, Tada T. Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies. Viruses. 2022; 14(6):1334. https://doi.org/10.3390/v14061334

Chicago/Turabian Style

Zhou, Hao, Belinda M. Dcosta, Nathaniel R. Landau, and Takuya Tada. 2022. "Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies" Viruses 14, no. 6: 1334. https://doi.org/10.3390/v14061334

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop